[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100652833":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":11,"centralContacts":20,"locations":11,"responsibleParty":26,"collaborators":11,"id":28,"slug":29,"hasResults":30,"nctId":31,"briefTitle":32,"officialTitle":33,"acronym":34,"eligibilityCriteria":35,"healthyVolunteers":30,"sex":36,"minAge":37,"maxAge":11,"enrollmentInfo":38,"targetDuration":11,"studyType":41,"phases":42,"briefSummary":44,"conditions":45,"keywords":11,"overallStatus":47,"whyStopped":11,"lastUpdateSubmitDate":48,"lastUpdatePostDateStruct":49,"startDateStruct":52,"completionDateStruct":54,"leadSponsor":56,"locationsCount":11},{"fullName":5,"class":6},"Bausch & Lomb Incorporated","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"BL1107 is sterile ophthalmic solution to be administered at varying concentrations","EXPERIMENTAL",null,[13],"Drug: BL1107",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":11},"DRUG","BL1107","BL1107 topical ocular solution",[9],[21],{"name":22,"role":23,"phone":24,"phoneExt":11,"email":25},"Johnson Varughese","CONTACT","9089271162","Johnson.Varughese@bausch.com",{"type":27,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100652833","phase-2-bl1107-response-and-intensity-guided-dosing-for-hyperemia-resolution-trial-100652833",false,"NCT07778888","BL1107 Response and Intensity Guided Dosing for Hyperemia Resolution Trial","Phase 2a Masked Trial to Identify the Lowest Effective Concentration of BL1107 for Conjunctival Hyperemia in Patients With Dry Eye Disease","BRIGHT","Inclusion Criteria:\n\n* Documented diagnosis of dry eye disease\n* Conjunctival hyperemia in both eyes, without clinical signs of infection or allergic conjunctivitis\n\nExclusion Criteria:\n\n* Any active ocular disease\n* Anticipated wearing of contact lenses during study\n\nAdditional criteria per protocol","ALL","18 Years",{"count":39,"type":40},20,"ESTIMATED","INTERVENTIONAL",[43],"PHASE2","Trial RX01-BL1107-1202 is designed to identify the lowest effective concentration of BL1107 required for complete resolution of conjunctival hyperemia in participants with DED. Participants will be masked to concentration of BL1107 received.",[46],"Dry Eye Disease","NOT_YET_RECRUITING","2026-08-18",{"date":50,"type":51},"2026-08-21","ACTUAL",{"date":53,"type":40},"2026-10",{"date":55,"type":40},"2027-02",{"name":5,"class":6}]